ROIVANT SCIENCES LTD. Proceeds from Divestiture of Interest in Consolidated Subsidiaries
ROIVANT SCIENCES LTD. (ROIV) reported Proceeds from Divestiture of Interest in Consolidated Subsidiaries of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries · last filed 2026-05-20
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for the quarter ending 2025-03-31 was $75.00M.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for the quarter ending 2024-12-31 was $75.20M.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2025 was $260.59M, a 448.60% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2024 was $47.50M.
- ROIVANT SCIENCES LTD. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2023 was $0.00.
| Period end | Proceeds from Divestiture of Interest in Consolidated Subsidiaries 3 month | Proceeds from Divestiture of Interest in Consolidated Subsidiaries 6 month | Proceeds from Divestiture of Interest in Consolidated Subsidiaries 9 month | Proceeds from Divestiture of Interest in Consolidated Subsidiaries 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 10-K · filed 2026-05-20 | |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $0.00 10-Q · filed 2026-02-06 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | |||
| 2025-03-31 | $75.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $150.20M derived: sum of 2 quarters · filed 2026-05-20 | $260.59M 10-K · filed 2026-05-20 | |
| 2024-12-31 | $75.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $185.59M 10-Q · filed 2026-02-06 | ||
| 2024-09-30 | $110.39M 10-Q · filed 2025-11-10 | |||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $47.50M 10-K · filed 2026-05-20 | |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $47.50M 10-Q · filed 2025-02-10 | ||
| 2023-09-30 | $47.50M 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $0.00 derived: sum of 2 quarters · filed 2025-05-29 | $0.00 10-K · filed 2025-05-29 | |
| 2022-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $0.00 10-Q · filed 2024-02-13 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |